By Karen Roman
SkylineDx said it published new peer-reviewed data where its Merlin CP-GEP Test outperforms the competition and current standards of care for identifying melanoma risk using molecular testing.
In response to a competitor’s study comparing its own test to the Merlin CP-GEP Test, SkylineDx released a follow-up study clarifying the misleading benchmarks originally released by the competitor, the company said.
SkylineDx’s subsequent study showed the Merlin CP-GEP Test accurately identifies high-risk patients with a higher positivity risk that traditional risk factors miss, it stated.
“Melanoma clinicians need tools that are not only innovative but proven through rigorous, prospective, and blinded clinical validation,” said Alexander Meves, MD, Mayo Clinic. “The Merlin CP-GEP Test has demonstrated an improvement over traditional clinicopathologic features and showed in the MERLIN_001 trial that High-Risk patients carry a significantly elevated risk—above key guideline thresholds.”
READ MORE
AlphaTON Capital: Capture the Best of Telegram Economics at a Steep Discount – Initiation Report
Register for our weekly newsletter HERE
Contact:
Click HERE to follow us on LinkedIn
